Clinical Trial Update: Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome [Phase 1, Phase 2]

View source ↗

Summary

This entry describes an ongoing Phase 1/2 clinical trial evaluating lumbrokinase in adults with Long COVID, Post-treatment Lyme Disease Syndrome, and Chronic Fa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Covid
• Myalgic Encephalomyelitis Chronic Fatigue Syndrome
• Post-treatment Lyme Disease Syndrome

Drugs mentioned

• Lumbrokinase (lumbrokinase)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Long Covid, Post-treatment Lyme Disease Syndrome | Phase 1, Phase 2 | Status: RECRUITING